P. Hérait

发表

[Non-Hodgkin lymphoma arising in a case of Waldmann's intestinal lymphangiectasis].

P. Hérait, C. Gisselbrecht, C. Fermé, 1985, Nouvelle revue francaise d'hematologie.

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models

H. Dombret, E. Raymond, P. Hérait, 2019, Leukemia & lymphoma.

Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples

P. Hérait, M. Riveiro, Elodie Odore, 2014 .

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies

B. Quesnel, P. Hérait, A. Stathis, 2016, Clinical Pharmacokinetics.

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

Christian Jacques, Lucile Awad, David Cunningham, 1998, The Lancet.

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.

P. Hérait, A. Adenis, P. Canal, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

S. Culine, P. Hérait, M. Marty, 2000, British Journal of Cancer.

Dose-finding study of weekly 24h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients

P. Hérait, G. Deplanque, J. Bereder, 2004 .

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.

P. Hérait, G. Deplanque, J. Bereder, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

CPT-11 (irinotecan) in the treatment of colorectal cancer.

M. Ducreux, P. Hérait, P. Rougier, 1995, European journal of cancer.

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

E. Van Cutsem, C. Punt, P. Hérait, 1999, European journal of cancer.

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.

G. Vassal, P. Hérait, J. Misset, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Very late recurrence of childhood acute lymphoblastic leukemia treated with chemoimmunotherapy: a report of three cases occurring 19, 11, and 9 years after discontinuation of chemotherapy.

P. Hérait, M. Hayat, M. Ghosn, 1989, Medical and pediatric oncology.

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

P. Hérait, F. Goldwasser, V. Girre, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Does treatment with ARA-C in low dosage cause differentiation of leukemic cells?

H. Tilly, P. Hérait, L. Degos, 1983, Blood.

A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients

P. Hérait, A. Monnier, J. Robert, 2004, Cancer Chemotherapy and Pharmacology.

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

G. Salles, M. Gleeson, P. Hérait, 2014 .

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.

P. Hérait, J. Armand, G. Chabot, 1994, Journal of the National Cancer Institute.

Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.

P. Hérait, P. Rougier, M. Riggi, 1993, Cancer research.

Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma.

P. Hérait, P. Rougier, C. Théodore, 1987, Cancer treatment reports.

5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies

A. Palumbo, H. Dombret, B. Quesnel, 2014 .

Abstract LB-231: A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies

H. Dombret, P. Hérait, Elodie Odore, 2014 .

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

B. Leber, P. Hérait, K. Rai, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O7.3BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies

A. Palumbo, H. Dombret, P. Hérait, 2015 .

HLA -A, -B and -DR Antigens in North African Patients with Nasopharyngeal Carcinoma

M. Lipinski, P. Hérait, T. Tursz, 2008 .

Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies

A. Palumbo, H. Dombret, B. Quesnel, 2014 .

Phase I dose finding study of irinotecan (CPT-11) over a short i.v. infusion combined with a fixed dose of 5-fluorouracil (5-FU) protracted continuous i.v. infusion in patients with advanced solid tumours

P. Hérait, L. Paz-Ares, A. Carcas, 1997 .

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

R. Labianca, P. Hérait, P. Rougier, 1998, The Lancet.

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

P. Hérait, J. Armand, A. Gouyette, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

S. Culine, T. Conroy, M. Ychou, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CPT-11-induced cholinergic effects in cancer patients.

P. Hérait, J. Armand, G. Chabot, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

S. Culine, P. Hérait, J. Armand, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetic and Pharmacodynamic Advantages of Pirarubicin over Adriamycin after Intraarterial Hepatic Administration in the Rabbit VX 2 T \ imor Model 1

P. Hérait, P. Rougier, M. Riggi, 2006 .

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

H. Dombret, B. Quesnel, P. Hérait, 2016, The Lancet. Haematology.

Analysis of Intratumoral Lymphocyte Subsets in Patients with Undifferentiated Nasopharyngeal Carcinoma

M. Lipinski, P. Hérait, T. Tursz, 1985 .

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

H. Dombret, A. Baruchel, P. Hérait, 2015, Oncotarget.

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

L. Cascione, P. Hérait, G. Inghirami, 2015, Clinical Cancer Research.

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

G. Salles, M. Gleeson, A. Palumbo, 2016, The Lancet. Haematology.

Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer

P. Hérait, P. Rougier, J. Armand, 1988, Investigational New Drugs.

Phase II study of mitozolomide (M & B 39,565) in head and neck cancer

P. Hérait, J. Armand, E. Cvitkovic, 1989, Medical oncology and tumor pharmacotherapy.

Associated chronic lymphocytic leukemia and multiple myeloma: origin from a single clone.

P. Hérait, J. Brouet, J. Fermand, 1985, Blood.

742 Pathophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhea (DD): A prospective assessment

G. Vassal, P. Hérait, S. Giacchetti, 1995 .

Lymphocyte subsets in tumour of patients with undifferentiated nasopharyngeal carcinoma: presence of lymphocytes with the phenotype of activated T cells.

M. Lipinski, P. Hérait, T. Tursz, 1987, British Journal of Cancer.

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

E. Raymond, P. Hérait, G. Deplanque, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin.

P. Hérait, M. Marty, N. Poutignat, 1992, European journal of cancer.

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.

M. Buyse, P. Hérait, P. Piedbois, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.

A. Ravaud, P. Hérait, A. Zannetti, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

P. Hérait, J. Armand, M. Marty, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High dose intensity of CPT-11 administered as single dose every 3 weeks: The instittut gustave roussy experience

P. Hérait, J. Armand, G. Chabot, 1993 .

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

H. Dombret, B. Quesnel, P. Hérait, 2014 .

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

E. Raymond, P. Hérait, G. Deplanque, 2012 .

HLA-A, -B, and -DR antigens in North African patients with nasopharyngeal carcinoma.

M. Lipinski, P. Hérait, T. Tursz, 1983, Tissue antigens.

Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer.

P. Hérait, P. Rougier, J. Droz, 1994, Cancer investigation.

Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.

T. Delozier, P. Hérait, F. Morvan, 1992, American journal of clinical oncology.

Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck.

M. van Glabbeke, P. Hérait, J. Armand, 1992, European journal of cancer.

Phase II trial of pirarubicin in the treatment of advanced bladder cancer

P. Hérait, J. Droz, J. Kattan, 1992, Investigational New Drugs.

Preclinical Study Of The Bromodomain Inhibitor OTX015 In Acute Myeloid (AML) and Lymphoid (ALL) Leukemias

H. Dombret, A. Baruchel, P. Hérait, 2013 .

Phase II Trials of Tetrahydropyranyl‐Adriamycin (Pirarubicin) on Renal and Colon Carcinoma, Melanoma, and Soft Tissue Sarcoma

P. Hérait, J. Armand, P. Fumoleau, 1993, American journal of clinical oncology.

Phase II study of pirarubicin in advanced non-small cell lung cancer.

R. Arriagada, P. Hérait, T. Tursz, 1989, European Journal of Cancer and Clinical Oncology.

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

S. Culine, P. Hérait, M. Marty, 2000, British Journal of Cancer.

A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients

P. Hérait, A. Monnier, J. Robert, 2004, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastases.

P. Hérait, P. Rougier, D. Elias, 1994, European journal of cancer.

Intra‐Arterial Hepatic Chemotherapy with Pirarubicin: Preclinical and Clinical Studies

P. Hérait, P. Rougier, D. Elias, 1990, American journal of clinical oncology.

Abstract A72: A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors.

G. Rabinovich, E. Raymond, P. Hérait, 2013 .